Novel riminophenazine compounds with improved anti-tumour properties

South African Journal of Science

Volumn 92, Issue 5, 1996, Pages 257-259

  Durandt, Chrisna ^a   Van Rensburg, Constance E J ^a   O'Sullivan, John F ^b   Anderson, Ronald ^a  

^a UNIVERSITY OF PRETORIA   (South Africa)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0029741517     PISSN: 00382353     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Barry V.C., Belton J.G., Conalty M.C , Denneny J.M., Edward D.W., O'Sullivan J.F., Twomey D and Winder F.A. (1957). A new series of phenazines (rimino-compounds) with high anti-tuberculosis activity. Nature 179, 1013-1015.
2. Barry V.C and Conalty M.C. (1965). The antimycobacterial activity of B663. Leprosy Rev 36, 3-7.
3. Yawalkar S.J. and Vischer W. (1979). Lamprene (clofazimine) in leprosy. Leprosy Rev. 50, 135-144.
4. Cline M J (1970). Drug potentiation of macrophage function. Infect. Immun. 2, 601-605.
5. 2, but not protein kinase C in the pro-oxidative interactions of clofazimine with human phagocytes. Biochem. Pharmacol 37, 4635-4641.
6. Weiss S J. and Slivka A. (1982). Monocyte and granulocyte-mediated tumor cell destruction J clin. Invest. 69, 255-262.
7. Savage J E., O'Sullivan J.F., Zeis B.M. and Anderson R. (1989). Investigation of the structural properties of dihydrophenazines which contribute to their pro-oxidative interactions with human phagocytes. J. antimicrob. Chemother. 23, 691-700.
8. +-adenosine triphosphatase activity of human lymphocytes by a lysophospholipid-dependent mechanism Biochem Pharmacol 46, 2029-2038.
9. 2 by human leucocytes. Leprosy Rev. 58, 383-388.
10. Zeis B.M., Anderson R. and O'Sullivan J F. (1988). Inhibition of mononuclear leukocyte transformation in vitro by dihydrophenazines in comparison to clofazimine. Leprosy Rev. 59, 31-35
11. Van Rensburg C.E.J., van Staden A.M. and Anderson R. (1993). The riminophenazine agents clofazimine and B669 inhibit the proliferation of cancer cell lines in vitro by phospholipase A2-mediated oxidative and nonoxidative mechanisms. Cancer Res. 53, 318-323.
12. Van Rensburg C E.J., Durandt C., Garlinski P.J and O'Sullivan J F (1993). Evaluation of the antineoplastic activities of the riminophenazine agents clofazimine and B669 in tumor-bearing rats and mice. Internat. J. Oncol. 3, 1011-1013.
13. +-adenosine triphosphatase activity in cancer cell lines in vitro Internat. J. Oncol. 4, 1115-1119.
14. Moore V.J (1983). A review of side-effects experienced by patients taking clofazimine. Leprosy Rev. 54, 327-335.
15. O'Sullivan J.F., Conalty M.L and Morrison N.E. (1988). Clofazimine analogues active against a clofazimine-resistant organism. J. med. Chem. 31, 567-572.
16. Babior B.M., Kipnes R S. and Curnutte J T. (1973) The production by leukocytes of superoxide, a potential bactericidal agent. J. clin. Invest. 52, 741-744.
17. Van Gelder B.F. and Slater E.C. (1962). The extinction coefficient of cytochrome c Biochim. Biophys. Acta 58, 593-595.
18. Garrelts J C (1991) Clofazimine: A review of its use in leprosy and Mycobacterium avium complex infection. DICP 25 525-531.